Re-screening for novel CD40-TRAF6 interaction inhibitors (TRAF-STOPs 2.0)

In this project, we aim to screen for new small molecule inhibitors, which can specifically block the inflammatory signals contributing to atherosclerosis as the dominating cause underlying cardiovascular disease, and may therefore serve as potential drug candidates for anti-inflammatory treatment.

Re-screening for novel CD40-TRAF6 interaction inhibitors (TRAF-STOPs 2.0)

Project Term
2021 - 2021
Granted Budget
€ 405.710
Indication
atherosclerosis
Therapeutic Principle
Drug
Principal Investigator
Dorothee Atzler, Christian Weber, Esther Lutgens (Hospital of Ludwig Maximilian University of Munich)